Takeaways From FDA's 1st Waiver Decision

Law360, New York (March 8, 2013, 11:45 AM EST) -- On Feb. 22, 2013, the U.S. Food and Drug Administration approved two generic drugs with a risk evaluation and mitigation strategies (REMS) program that differed from the innovator company’s existing REMS program. This decision appears to be the first time that the FDA has waived the requirement for a “single shared system” under Section 505-1 of the federal Food, Drug and Cosmetic Act (FDC Act), which was created by Section 901 of the Food and Drug Administration Amendments Act of 2007 (the FDAAA).

According to the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.